Research and Markets has announced the addition of the "Neurofibromatoses Type II - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neurofibromatoses Type II and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Introduction
- Neurofibromatoses Type II Overview
- Therapeutics Development
- Pipeline Products for Neurofibromatoses Type II - Overview
- Pipeline Products for Neurofibromatoses Type II - Comparative Analysis
- Neurofibromatoses Type II - Therapeutics under Development by Companies
- Neurofibromatoses Type II - Therapeutics under Investigation by Universities/Institutes
- Neurofibromatoses Type II Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Neurofibromatoses Type II - Products under Development by Companies
- Neurofibromatoses Type II - Products under Investigation by Universities/Institutes
- Neurofibromatoses Type II - Companies Involved in Therapeutics Development
- Arno Therapeutics, Inc.
- CalAsia Pharmaceuticals, Inc.
- Lixte Biotechnology Holdings, Inc.
- Novartis AG
For more information visit http://www.researchandmarkets.com/research/4k83xl/neurofibromatoses
View source version on businesswire.com: http://www.businesswire.com/news/home/20160526006167/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716